Associated Genetic Biomarkers
Immunoglobulin lambda locus (IGL) is a gene that encodes for a variable region in immunoglobulins, protein complexes that recognize foreign antigens and initiate immune responses. Amplification is observed in prostate cancer.
IGL is altered in 0.19% of all cancers with breast invasive ductal carcinoma, diffuse large B-cell lymphoma, not otherwise specified, endometrial endometrioid adenocarcinoma, bladder urothelial carcinoma, and Burkitt lymphoma having the greatest prevalence of alterations .
The most common alterations in IGL are IGL-MYC Fusion (0.18%), IGL-BCL2 Fusion (0.04%), IGL Fusion (0.03%), and IGL-TTC28 Fusion (1.09%) .
IGL status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain IGL status as an inclusion criterion, 2 are phase 2 (2 open).
Trials with IGL status in the inclusion eligibility criteria most commonly target B-cell acute lymphoblastic leukemia .
The most frequent alteration to serve as an inclusion eligibility criterion is IGL Fusion .
Blinatumomab and inotuzumab ozogamicin are the most frequent therapies in trials with IGL as an inclusion criteria .
Significance of IGL in Diseases
B-Cell Acute Lymphoblastic Leukemia +
IGL is an inclusion criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain IGL status and B-cell acute lymphoblastic leukemia as inclusion criteria, 2 are phase 2 (2 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.